Advertisement

Insulin-Sensitizing Effect of Peroxisome Proliferator Activated Receptor Gamma Agonist on Serum Visfatin Levels in High Fat Diet Induced Type 2 Diabetes Mellitus

  • Arshia Tabassum
  • Tabassum Mahboob
Research Paper

Abstract

The aim of the study was to find the correlation between serum visfatin, glucose and insulin homeostasis in high fat diet (HFD) induced type 2 diabetes mellitus (T2DM). The study also focuses on the insulin sensitizing effects of peroxisomes proliferator-activated receptor gamma activation via agonist (rosiglitazone) in the regulation of serum visfatin levels. The study was performed in Wistar rats (180–220 g), categorized into five groups. Group 1: Control animals remain fed on a normal rat diet, Group 2: HFD-fed group, Group 3: HFD treated group, treated with rosiglitazone (RSG) for 7 days, Group 4: T2DM group and Group 5: T2DM treated group, treated with rosiglitazone for 7 days. The experimental model of T2DM was developed by feeding rats with HFD for 8 weeks and a low dose of streptozotocin (i.p. 35 mg/ml/kg body weight). Anthropometric parameters, blood glucose, serum visfatin and insulin level, insulin sensitivity and insulin resistance (HOMA-IR, HOMA-β and QUICKI) were estimated. The correlation between visfatin levels and insulin resistance in all groups were also investigated. Hyperglycaemia in HFD-induced T2DM elevated the serum insulin and visfatin levels. Increased insulin resistance was also observed in HFD fed and T2DM rats. Administration of rosiglitazone significantly decreases the insulin resistance by increasing the insulin sensitivity and decreased serum visfatin in HFD and T2DM rats. In conclusion increased serum visfatin levels in HFD and T2DM are a probable early diagnostic biomarker for diabetic complications. That could be reversed by insulin sensitization to improve endothelial function in T2DM patients in future.

Keywords

Insulin resistance High fat diet Obesity HOMA-IR Type 2 diabetes 

References

  1. Alghasham AA, Barakat YA (2008) Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi Med J 29(2):185–192Google Scholar
  2. Bermudez V, Finol F, Parra N, Parra M, Pérez A, Penaranda L, Vílchez D, Rojas J, Arráiz N, Velasco M (2010) PPAR-γ agonists and their role in type 2 diabetes mellitus management. Am J Ther 17(3):274–283CrossRefGoogle Scholar
  3. Bernardis LL (1970) Prediction of carcass fat, water and lean body mass from Lee’s ‘nutritive ratio’ in rats with hypothalamic obesity. Cell Mol Life Sci 26(7):789–790CrossRefGoogle Scholar
  4. Bhaswant M, Poudyal H, Mathai ML, Ward LC, Mouatt P, Brown L (2015) Green and black cardamom in a diet-induced rat model of metabolic syndrome. Nutrients 7(9):7691–7707CrossRefGoogle Scholar
  5. Caprio S, Perry R, Kursawe R (2017) Adolescent obesity and insulin resistance: roles of ectopic fat accumulation and adipose inflammation. Gastroenterology 152(7):1638–1646CrossRefGoogle Scholar
  6. Chang YC, Chang TJ, Lee WJ, Chuang LM (2010) The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 59:93–99CrossRefGoogle Scholar
  7. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H, Kilinc M (2009) Plasma visfatin concentrations in childhood obesity: relationships to insulin resistance and anthropometric indices. Swiss Med Wkly 139:22–27Google Scholar
  8. Edrees HM, Morgan EN (2013) Improvement of insulin sensitivity by rosiglitazone decreased the visfatin level in obese rats induced by high fat diet. Int J Diabetes Res 2(2):27–32.  https://doi.org/10.5923/j.diabetes.20130202.02 Google Scholar
  9. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI (2011) Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60:63–70CrossRefGoogle Scholar
  10. Fujitani Y, Ueno T, Watada H, Autophagy in Health and Disease (2010) The role of pancreatic β-cell autophagy in health and diabetes. Am J Physiol Cell Physiol 299(1):C1–C6CrossRefGoogle Scholar
  11. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430CrossRefGoogle Scholar
  12. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114(12):1752–1761CrossRefGoogle Scholar
  13. Greenfield JR, Chisholm DJ (2004) Thiazolidinediones-mechanisms of action. Aust Prescr 27(3):67.  https://doi.org/10.18773/austprescr.2004.059 CrossRefGoogle Scholar
  14. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC (2010) Effect of rosiglitazone and ramipril on β-cell function in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care 33(3):608–613CrossRefGoogle Scholar
  15. Hariri N, Thibault L (2010) High-fat diet-induced obesity in animal models. Nutr Res Rev 23(2):270–299CrossRefGoogle Scholar
  16. Kamińska A, Kopczyńska E, Bronisz A, Żmudzińska M, Bieliński M, Borkowska A, Tyrakowski T, Junik R (2010) An evaluation of visfatin levels in obese subjects. Endokrynol Pol 61(2):169–173Google Scholar
  17. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85(7):2402–2410CrossRefGoogle Scholar
  18. Khalifa MMA, Mangoura SA, El-Moselhy MA, El-Daly ME (2009) The effectiveness of beta adrenoceptor antagonists on progression of insulin resistance and type 2 diabetes in high fat diet-fed rats. Saudi Pharm J 17(1):19–28Google Scholar
  19. Klöting N, Klöting I (2005) Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 332(4):1070–1072CrossRefGoogle Scholar
  20. Lan J, Chen X, Chen X, Wang S, Zhang X, Wu K, He S, Peng Y, Jiang L, Li L, Wan L (2011) The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance. Diabetes Res Clin Pract 94:71–76CrossRefGoogle Scholar
  21. Legakis I, Mantzouridis T, Bouboulis G, Chrousos GP (2016) Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab 60(1):76–78CrossRefGoogle Scholar
  22. Lenzen S (2008) The mechanisms of alloxan and streptozotocin induced diabetes. Diabetologia 51(2):216–226.  https://doi.org/10.1007/s00125-007-0886-7 CrossRefGoogle Scholar
  23. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R, Reaven GM (1998) Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47(6):663–668CrossRefGoogle Scholar
  24. Lutz TA, Woods SC (2012) Overview of animal models of obesity. Curr Protoc Pharmacol 5–61.  https://doi.org/10.1002/0471141755.ph0561s58
  25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefGoogle Scholar
  26. McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM (2013) Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol 4:52.  https://doi.org/10.3389/fendo.2013.00052 CrossRefGoogle Scholar
  27. McGee KC, Harte AL, da Silva NF, Al-Daghri N, Creely SJ, Kusminski CM, Tripathi G, Levick PL, Khanolkar M, Evans M, Chittari MV, Patel V, Kumar S, McTernan PG (2011) Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and abdominal subcutaneous adipocytes. PLoS One 6(6):e20287CrossRefGoogle Scholar
  28. Odegaard JI, Chawla A (2013) Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339(6116):172–177CrossRefGoogle Scholar
  29. Qatanani M, Lazar MA (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21(12):1443–1455CrossRefGoogle Scholar
  30. Rull A, Geeraert B, Aragonès G, Beltrán-Debón R, Rodríguez-Gallego E, García-Heredia A, Pedro-Botet J, Joven J, Holvoet P, Camps J (2014) Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study. J Proteome Res 13(3):1731–1743CrossRefGoogle Scholar
  31. Srinivasan K, Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125(3):451–472Google Scholar
  32. Srinivasan K, Viswanad B, Asrat L et al (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313–320CrossRefGoogle Scholar
  33. Stromsdorfer KL, Yamaguchi S, Yoon MJ, Moseley AC, Franczyk MP, Kelly SC, Qi N, Imai SI, Yoshino J (2016) NAMPT-mediated NAD + biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep 16(7):1851–1860CrossRefGoogle Scholar
  34. Taşkesen D, Kirel B, Us T (2012) Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 4(2):76–81CrossRefGoogle Scholar
  35. Tian J, Wong WT, Tian XY, Zhang P, Huang Y, Wang N (2010) Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension 56(1):129–135CrossRefGoogle Scholar
  36. Xu L, Kitade H, Ni Y, Ota T (2015) Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules 5(3):1563–1579CrossRefGoogle Scholar
  37. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351(11):1106–1118CrossRefGoogle Scholar
  38. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H et al (2003) The rat model of type 2 diabetes mellitus and its glycometabolism characters. Exp Anim 52:401–407CrossRefGoogle Scholar
  39. Zoair MA (2012) Role of visfatine in glucose and insulin homeostasis in fatty albino rats. Nat Sci 10:172–177.  https://doi.org/10.7537/marsnsj101012.25 Google Scholar

Copyright information

© Shiraz University 2018

Authors and Affiliations

  1. 1.Department of BiochemistryUniversity of KarachiKarachiPakistan

Personalised recommendations